<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270462</url>
  </required_header>
  <id_info>
    <org_study_id>17-0781</org_study_id>
    <nct_id>NCT03270462</nct_id>
  </id_info>
  <brief_title>CNS Study of Patients Switching From Tacrolimus to Envarsus</brief_title>
  <official_title>A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study documenting the neurotoxic side effects including tremors in patients
      with a stable graft who are receiving Tacrolimus following kidney transplantation. A
      standardized questionnaire will be used to document these symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunosuppressive therapies have burdensome side effects which may lead to sub-therapeutic
      dosing and non-compliance.

      This study provides renal transplant patients the opportunity for an alternative treatment
      using tacrolimus, with possible less Central Nervous Symptom (CNS) side effects. CNS side
      effects are one of the main reasons that patients complain about after having a kidney
      transplant while on tacrolimus (Prograf). The side effects can be debilitating and can affect
      the patient's overall well-being. In severe cases it may lead to non-compliance. The
      advantage of the study of using Envarsus is the ability to avoid these debilitating CNS side
      effects and afford better compliance with the patients taking the medicine.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline, 1 Month, 6 Months</time_frame>
    <description>The Investigators will evaluate the quality of life between baseline and 6 months related to sleep disturbance and upper extremity fine motor skills/ADL (activities of daily living), with the goal to be an improvement in their quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Kidney Function related to Tacrolimus drug levels</measure>
    <time_frame>Baseline, 1 Month, 6 Months</time_frame>
    <description>The Investigators will evaluate Tacrolimus drug levels and will document any adverse events associated with this measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kidney Function related to serum creatinine levels</measure>
    <time_frame>Baseline, 1 Month, 6 Months</time_frame>
    <description>The Investigators will evaluate serum creatinine levels and will document any adverse events associated with this measure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Renal Transplant Patients</condition>
  <arm_group>
    <arm_group_label>Envarsus XR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envarsus XR</intervention_name>
    <description>Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.</description>
    <arm_group_label>Envarsus XR</arm_group_label>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients with stable graft function.

          -  More than 1 months post-transplant.

          -  18+ years of age with some CNS problems secondary to Prograf (tacrolimus).

        Exclusion Criteria:

          -  Multi-organ patients (kidney/pancreas, kidney/liver).

          -  Evidence of graft rejection or treatment of acute rejection within 14 days prior to
             baseline visit.

          -  Inability to self-administer the QOL questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lisa Kornfeld</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

